Phenotypes Associated with This Genotype

Genotype
MGI:3836424

• Allelic Composition: Aurka^tm1.1Tvd/Aurka^tm1.1Tvd; Gt(ROSA)26Sor^{tm1(cre/ERT)Nat}/Gt(ROSA)26Sor^tm1Sor
• Genetic Background: involves: 129 * 129P2/OlaHsd * 129S4/SvJaeSor * C57BL/6J

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

cellular

abnormal cell nucleus morphology ( J:145744 )

• in MEFs at later time points after OHT treatment and serum addition cells develop large aberrant nuclei with frequent micronuclei

abnormal chromosome number ( J:145744 )

• in MEFS after OHT treatment and serum addition increases in the population of cells with 4N and 8N DNA content are seen

abnormal mitosis ( J:145744 )

• live cell imaging indicates a median 8 h delay in mitotic entry in MEFS after OHT treatment and serum addition compared to controls

• in MEFS after OHT treatment and serum addition more cells are in prophase and most of these show an early prophase phenotype

• in MEFS after OHT treatment and serum addition almost no cells in metaphase, anaphase, and telophase are detected

• in MEFS after OHT treatment and serum addition cells in prometaphase have a monopolar spindle with closely adjacent chromosomes, the presence of these monopolar spindles activates the spindle checkpoint

increased mitotic index ( J:145744 )

• in MEFS 28 h after OHT treatment and serum addition the percent of cells positive for PH3 is increased about 3 fold compared to controls

• however, the timing of the peak in PH3 positive cells is similar to controls

decreased cell proliferation ( J:145744 )

• growth defect in MEFs following OHT treatment and serum addition